Abeona reports building ZEVASKYN launch momentum; payer coverage reaches 80% of commercial lives

ABEONA THERAPEUTICS INC.

First patient treated with ZEVASKYN in Dec 2025; manufacturing resumed Jan 2026, multiple biopsies collected, additional scheduled.
All major commercial payers (United Healthcare, Cigna, Aetna, Anthem, most BCBS) now cover ZEVASKYN, representing ~80% of commercial lives.
CMS established permanent HCPCS J-code (J3389) effective Jan 1, 2026; coverage also secured across all Medicaid programs.
Initial Qualified Treatment Centers gaining familiarity with administrative processes; growing patient and physician interest.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.